VERVE THERAPEUTICS
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.
VERVE THERAPEUTICS
Industry:
Biotechnology Genetics Life Science
Founded:
2018-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.vervetx.com
Total Employee:
101+
Status:
Active
Contact:
+1 617 603 0070
Total Funding:
419.3 M USD
Technology used in webpage:
Amazon CrUX Top 50m AWS Global Accelerator Greenhouse
Similar Organizations
Myeloid Therapeutics
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapyโbased treatments for cardiovascular disease.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
SmartLabs
SmartLabs builds and operates enterprise-grade labs, including multi-use R&D labs, vivariums, process development, and manufacturing suites.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Eli Lilly
Eli Lilly investment in Post-IPO Equity - Verve Therapeutics
Wellington Management
Wellington Management investment in Series B - Verve Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Verve Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Verve Therapeutics
Redmile Group
Redmile Group investment in Series B - Verve Therapeutics
Logos Capital
Logos Capital investment in Series B - Verve Therapeutics
Casdin Capital
Casdin Capital investment in Series B - Verve Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Verve Therapeutics
Novo Holdings
Novo Holdings investment in Series B - Verve Therapeutics
Biomatics Capital Partners
Biomatics Capital Partners investment in Series B - Verve Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-05-31 | Verve Therapeutics names Lister as chief scientific officer |
Official Site Inspections
http://www.vervetx.com Semrush global rank: 1.41 M Semrush visits lastest month: 18.07 K
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Verve Therapeutics"
Investor Relations | Verve Therapeutics
May 28, 2025 The Investor Relations website contains information about Verve Therapeutics's business for stockholders, potential investors, and financial analysts.See details»
Company: Verve Therapeutics - CRISPR Medicine
Verve Therapeutics is a pre-clinical stage gene-editing company that focuses on developing novel therapies for genetic cardiovascular diseases. The company holds multiple licenses from The โฆSee details»
Verve Therapeutics Information - RocketReach
Verve Therapeutics is a Biotechnology Research, Biotechnology, and Science and Engineering company located in Boston, Massachusetts with $32.3 million in revenue and 309 employees. โฆSee details»
Meet Our Team | Verve Therapeutics
Verve was purpose-built to disrupt todayโs chronic care model for cardiovascular disease, with a team of experts in cardiovascular medicine, genetics, gene editing, delivery technologies and โฆSee details»
Verve Therapeutics - Crunchbase Company Profile & Funding
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.See details»
Vertex and Verve Therapeutics Establish Collaboration to Discover โฆ
Jul 20, 2022 Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and Royalties BOSTON and CAMBRIDGE, Mass., July 20, โฆSee details»
Verve Therapeutics, Inc. (Verve Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธ โฆ
May 7, 2025 VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory โฆSee details»
Lilly to acquire Verve Therapeutics to advance one-time โฆ
5 days ago For more information, please visit www.VerveTx.com. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've โฆSee details»
Lilly to acquire Verve Therapeutics to advance one-time ... - Nasdaq
5 days ago For more information, please visit www.VerveTx.com. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world.See details»
Our Story | Verve Therapeutics
At Verve, we are striving to build the preeminent company developing gene editing medicines to treat atherosclerotic cardiovascular disease (ASCVD). โฆSee details»
SEC Filing | Verve Therapeutics
CVD remains the leading cause of death worldwide, responsible for nearly one in three deaths according to the World Health Organization. It is also a leading contributor to reductions in life โฆSee details»
Contact | Verve Therapeutics
Verve Therapeutics 201 Brookline Avenue Boston, MA 02215 (617) 603-0070See details»
Verve Therapeutics · GitHub
GitHub is where Verve Therapeutics builds software.People This organization has no public members. You must be a member to see whoโs a part of this organization.See details»
Verve Therapeutics Receives U.S. FDA Fast Track Designation for โฆ
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that โฆSee details»
Our Pipeline | Verve Therapeutics
Our initial focus will be on adults with familial hypercholesterolemia (FH), a genetic disease that leads to lifelong severely elevated LDL-C that increases the risk of early-onset atherosclerotic โฆSee details»
Lilly to acquire Verve Therapeutics to advance one-time โฆ
5 days ago For more information, please visit www.VerveTx.com. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world.See details»
Culture & Careers | Verve Therapeutics
Fraudulent Job Offers Verve is aware that some job seekers have received false employment offers or recruitment emails from an individual or organization posing as Verve.See details»
SEC Filing | Verve Therapeutics
Organization and Corporate Power; Subsidiary. (a) The Company is a corporation validly existing and in good standing under the Laws of the State of Delaware, with full corporate power and โฆSee details»
Medical Professionals | Verve Therapeutics
We are committed to working closely with medical professionals worldwide to improve the current care model for cardiovascular disease with our gene editing programs.See details»
Verve Therapeutics Announces Positive Initial Data from the Heart โฆ
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced โฆSee details»